Chardan Capital Reaffirms “Buy” Rating for Emergent Biosolutions (NYSE:EBS)

Share on StockTwits

Chardan Capital reiterated their buy rating on shares of Emergent Biosolutions (NYSE:EBS) in a research report released on Thursday morning, AnalystRatings.com reports. Chardan Capital currently has a $71.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the stock. ValuEngine upgraded shares of Emergent Biosolutions from a hold rating to a buy rating in a research note on Wednesday, September 4th. Wells Fargo & Co upgraded shares of Emergent Biosolutions from a market perform rating to an outperform rating and lifted their price target for the stock from $61.00 to $64.00 in a research note on Wednesday, September 4th. Laidlaw set a $72.00 price target on shares of Emergent Biosolutions and gave the stock a buy rating in a research note on Wednesday, September 4th. Cowen reiterated a hold rating and issued a $67.00 price target on shares of Emergent Biosolutions in a research note on Thursday. Finally, Guggenheim initiated coverage on shares of Emergent Biosolutions in a research note on Thursday, September 12th. They issued a buy rating and a $65.00 price target for the company. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $69.00.

Shares of NYSE EBS traded down $0.96 during midday trading on Thursday, hitting $54.04. The company’s stock had a trading volume of 350,011 shares, compared to its average volume of 451,394. The business’s fifty day simple moving average is $54.01 and its two-hundred day simple moving average is $48.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.30 and a quick ratio of 1.53. Emergent Biosolutions has a 1 year low of $39.11 and a 1 year high of $73.89. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 0.96 and a beta of 1.55.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.58. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The business had revenue of $311.80 million during the quarter, compared to analyst estimates of $289.16 million. During the same quarter last year, the firm posted $0.55 earnings per share. The business’s revenue for the quarter was up 79.6% compared to the same quarter last year. Analysts anticipate that Emergent Biosolutions will post 3.04 EPS for the current fiscal year.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,509 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $56.12, for a total transaction of $84,685.08. Following the sale, the director now owns 21,494 shares of the company’s stock, valued at $1,206,243.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Vaughan Nelson Investment Management L.P. raised its holdings in Emergent Biosolutions by 18.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 677,628 shares of the biopharmaceutical company’s stock worth $35,426,000 after purchasing an additional 106,219 shares in the last quarter. Boston Advisors LLC raised its holdings in Emergent Biosolutions by 84.6% during the third quarter. Boston Advisors LLC now owns 57,003 shares of the biopharmaceutical company’s stock worth $2,980,000 after purchasing an additional 26,122 shares in the last quarter. Tygh Capital Management Inc. raised its holdings in Emergent Biosolutions by 211.1% during the third quarter. Tygh Capital Management Inc. now owns 298,488 shares of the biopharmaceutical company’s stock worth $15,605,000 after purchasing an additional 202,527 shares in the last quarter. Eagle Asset Management Inc. raised its holdings in Emergent Biosolutions by 1.8% during the third quarter. Eagle Asset Management Inc. now owns 312,224 shares of the biopharmaceutical company’s stock worth $16,323,000 after purchasing an additional 5,592 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Emergent Biosolutions by 17.5% during the third quarter. SG Americas Securities LLC now owns 3,612 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 538 shares in the last quarter. 87.75% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Recommended Story: What is Liquidity?

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.